臺灣博碩士論文加值系統

2007年12月美國財務會計準則委員會發布財務會計準則公報第141號「企業合併」之修訂版本，其中針對併購取得研發中無形資產 (In-process research and development) 之會計處理有大幅變動，舉凡基準日在2008年12月15日後所發生的企業合併，其併購取得研發中無形資產將從過去直接立即費用化轉變為資本化，視其為一項無確定耐用年限之無形資產，後續年度必須每年進行減損測試。配合目前美國生技與醫藥產業中企業間併購交易之興盛，本文將以該產業為研究核心，彙總2009至2012年間該產業內含資本化併購取得之研發中無形資產的98筆交易案件，並以現金流量觀點來檢驗該資產資本化之適切性，除此之外，本研究也檢驗各項減損指標與該項無形資產之關聯性。實證結果顯示，併購取得研發中之無形資產原始金額的確與未來一年度的營運現金流量呈現高度顯著關聯性，支持會計準則修改之合理性，同時也辨認出五項減損指標與該資產之後續減損情形顯著相關。最後，本研究從該產業中各家公司財務報導資訊中整理出併購取得之研發中無形資產認列減損之各項原因。

The Financial Accounting Standards Board (FASB) released a revised version of Statement of Financial Accounting Standards No. 141 (SFAS No. 141(R)) in December 2007. Accounting treatments of acquired in-process research and development (IPR&;D) in a business combination change from expensing to capitalizing as an indefinite-life intangible asset, and need to perform annual impairment test subsequently. Combining the above changes with the thriving M&;A activities trend in U.S. biotech and pharmaceuti&;#172;cal industry, this research will focus on the industry, summarize M&;A transactions including acquired IPR&;D capitalization happened in the period of 2009-2012 and inspect the appropriateness of acquired IPR&;D capitalization. Examination the association between impairment indicators and write-offs of acquired IPR&;D is also performed. Empirical results reveal that acquired IPR&;D amount and subsequent one-year operating cash flows are correlated significantly in the sample of 98 observations. Five impairment indicators are identified that being related with acquired IPR&;D impairment recogni&;#172;tion. This research also collects possible reasons that result in the impairment.

口試委員會審定書 #
誌謝 i
中文摘要 ii
ABSTRACT iii
CONTENTS iv
LIST OF FIGURE vi
LIST OF TABLES vii
Chapter 1 Introduction 1
Chapter 2 Prior Research 8
2.1 M&;A transactions in pharmaceutical industry 8
2.2 The change of accounting treatments on acquired IPR&;D 9
2.3 Relevant research 13
2.3.1 Capitalization of acquired IPR&;D 13
2.3.2 Impairment indicators of assets impairment 13
2.4 Hypotheses 15
Chapter 3 Data Resource and Research Methods 18
3.1 Sample construction and data characteristics 18
3.2 Empirical specification 19
3.2.1 The capitalization inspection model 19
3.2.2 The impairment inspection model 20
Chapter 4 Empirical Results 23
4.1 Descriptive statistics 23
4.2 Regression results 24
Chapter 5 Conclusion 27
Chapter 6 References 29

Aggarwal, S. (2014). What’s fueling the biotech engine – 2012 to 2013. Nature Biotechnology, 32, 32-39.
Alshwer, A. A., Sibilkov, V. and Zaiats, N. (2012). Financial Constraints and the Method of Payment in Mergers and Acquisitions. Working paper.
Andrews, C., Falmer, J., Riley, J., Todd, C. and Volkan, A. (2009). SFAS 141(R): Global Convergence and Massive Changes in M&;A Accounting. Journal of Business &; Economics Research, 7, 125-136.
Arrowsmith, J. (2012). A decade of change. Nature Reviews Drug Discovery, 11, 17-18.
Betty, A. and Weber, J. (2006). Accounting Discretion in Fair Value Estimates: An Examination of SFAS 142 Goodwill Impairments. Journal of Accounting Research, 44(2), 257-288.
Chakrabarti, A., Hauschildt, J. and Suverkrup, C. (1996). Does it pay to acquire technological firms? R&;D Management, 24(1), 47-56.
Comanor, W. S. and Scherer, F. M. (2013). Mergers and Innovation in the Pharmaceutical industry. Journal of Health Economics, 32, 106-113.
Deng, Z. and Lev, B. (2006). In-process R&;D: To capitalize or expense? Journal of Engineering and Technology Management, 23(1-2), 18-32.
Financial Accounting Standards Board (FASB). (1974). Statement No.2, Accounting for Research and Development Costs. (Financial Accounting Standards Board, Norwalk, CT).
(1975). Interpretation No.4, Applicability of FASB Statement No.2 to Business Combinations Accounted for by the Purchase Method: An Interpretation of FASB Statement No.2. (Financial Accounting Standards Board, Norwalk, CT).
(2001). Statement No.142, Goodwill and Other Intangible Assets. (Financial Accounting Standards Board, Norwalk, CT).
(2007). Statement No.141 (Revised), Business Combinations. (Financial Accounting Standards Board, Norwalk, CT).
Gu, F. and Lev, G. (2011). Overpriced Shares, Ill-Advised Acquisitions, and Goodwill Impairment. The Accounting Review, 86(6), 1995-2022.
Hayn, C. and Hughes, P. J. (2006). Leading Indicators of Goodwill Impairment. Journal of Accounting, Auditing &; Finance, 21, 223-265.
IMS Health. (2013). The Global Use of Medicines: Outlook through 2017. Danbury, United States: IMS Health.
KPMG. (2011). Future Pharma: Five Strategies to Accelerate to Transformation of the Pharmaceutical Industry by 2020. Amstelveen, Netherlands: KPMG International.
Malik, N. N. (2009). Biotech acquisitions by big pharma: why and what is next. Drug Discovery Today, 14(17-18), 818-821.
Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery, 8, 959-968.
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R. and Schacht A. L. (2010). How to improve R&;D productivity: the pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery, 9, 203-214.
Peetathawatchai, P. and Acaranupong, K. (2012). Are impairment indicators and losses associated in Thailand? Journal of Financial Reporting and Accounting, 10(1), 95-114.
PricewaterhouseCoopers. (2013). Global Top 100: Companies by Market Capitalization. London, United Kingdom: PricewaterhouseCoopers International.
(2013). US GAAP: Issues and Solutions for the Pharmaceuticals and Life Sciences Industries. London, United Kingdom: PricewaterhouseCoopers International.
Schmid, A. S., Sanchez, C. M. and Goldberg, S. R. (2012). M&;A Today: Great Challenges, but Great Opportunities. Journal of Corporate Accounting &; Finance, 23(2), 3-8.
Schon, B. and Pyka, A. (2009). Mergers &; Acquisitions – Their Impact on the Innovativeness of Single Firms and Entire Industries. Presented at “Firms, Markets and Innovation” Thematic Meeting of the French Economic Association (AFSE), Sophia Antipolis, France.
Villiger, R. (2009). Licensing: pros and cons for technology. Drug Discovery Today, 14(5-6), 227-230.
Weiss, D., Naik, P. and Weiss, R. (2009). The ‘big pharma’ dilemma: develop new drug or promote existing ones? Nature Reviews Drug Discovery, 8, 533-534.